Nalbuphine ER: Relief is Possible

We are developing nalbuphine ER, unlocking new market opportunities and the potential to significantly improve the quality of life of patients suffering from the serious symptoms associated with chronic neurologically mediated conditions.

Passionate
about Progress

Backed by expert scientific and medical advisors and dedicated to our investors, the Trevi leadership team is highly engaged and experienced in life science clinical development, successful commercialization, and building companies of exceptional value.

Passionate
about Progress

Backed by expert scientific and medical advisors and dedicated to our investors, the Trevi leadership team is highly engaged and experienced in life science clinical development, successful commercialization, and building companies of exceptional value.

Are you suffering from or caring for someone with symptoms associated with chronic neurologically mediated conditions?

A New Hope for Patients with Chronic and Serious Neurologically Mediated Conditions

We are developing nalbuphine ER as an oral treatment for a broad range of chronic conditions for which patients have few, if any, treatment options. With its unique dual mechanism of action, nalbuphine ER has the potential to significantly improve the quality of life of patients.

Committed to Excellence in Pharmaceutical Development and Bringing Solutions to Patients

news

06/18/2019

NEW HAVEN, Conn. , June 18, 2019 (GLOBE NEWSWIRE) -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company focused on the development and commercialization of nalbuphine ER to treat serious neurologically mediated conditions, today announced that Company management

06/13/2019

Raised $70 Million in Gross Proceeds from Initial Public Offering and Concurrent Private Placement Initiated Phase 2 Clinical Trial for Chronic Cough in Patients with Idiopathic Pulmonary Fibrosis (IPF)   NEW HAVEN, Conn. , June 13, 2019 (GLOBE NEWSWIRE) -- Trevi Therapeutics, Inc.

05/07/2019

NEW HAVEN, Conn. , May 07, 2019 (GLOBE NEWSWIRE) -- Trevi Therapeutics, Inc. (“Trevi”), a clinical-stage biopharmaceutical company focused on the development and commercialization of nalbuphine ER to treat serious neurologically mediated conditions, today announced the pricing of its initial public

contact

Trevi Therapeutics

195 Church Street, 14th Floor
New Haven, CT 06510
map

(203) 304-2499
email us